ro 363 has been researched along with cl 316243 in 1 studies
| Studies (ro 363) | Trials (ro 363) | Recent Studies (post-2010) (ro 363) | Studies (cl 316243) | Trials (cl 316243) | Recent Studies (post-2010) (cl 316243) |
|---|---|---|---|---|---|
| 23 | 0 | 0 | 291 | 1 | 108 |
| Protein | Taxonomy | ro 363 (IC50) | cl 316243 (IC50) |
|---|---|---|---|
| Beta-2 adrenergic receptor | Rattus norvegicus (Norway rat) | 9.7724 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allen, MJ; Coleman, RA | 1 |
1 other study(ies) available for ro 363 and cl 316243
| Article | Year |
|---|---|
Beta 2-adrenoceptors mediate a reduction in endothelial permeability in vitro.
Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Albumins; Albuterol; Analysis of Variance; Animals; Capillary Permeability; Catechols; Cattle; Cells, Cultured; Dioxoles; Dose-Response Relationship, Drug; Endothelium, Vascular; Evans Blue; Hydrogen Peroxide; Isoproterenol; Lipopolysaccharides; Nitroprusside; Propanolamines; Prostaglandin Endoperoxides, Synthetic; Pulmonary Artery; Receptors, Adrenergic, beta-2; Salmeterol Xinafoate; Thrombin; Thromboxane A2; Vasoconstrictor Agents | 1995 |